5-溴-4-氯-2-羟基苯甲酸 | 142167-38-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 5-溴-4-氯-2-羟基苯甲酸
• 英文名称: 5-bromo-4-chloro-2-hydroxybenzoic acid
• 英文别名: 5-bromo-4-chlorosalicylic acid；5-bromo-4-chloro-2-hydroxy-benzoic acid
• CAS: 142167-38-2
• 化学式: C₇H₄BrClO₃
• 分子量: 251.464
• InChiKey: XUKLAPBPFXGIOW-UHFFFAOYSA-N

物化性质

• 沸点：
  370.8±42.0 °C(Predicted)
• 密度：
  1.956±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2918290000

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-Bromo-4-chloro-2-hydroxybenzoic acid
Synonyms: 5-Bromo-4-chlorosalicylic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-Bromo-4-chloro-2-hydroxybenzoic acid
CAS number: 142167-38-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H4BrClO3
Molecular weight: 251.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-溴-4-氯-2-羟基苯甲酸 在 哌啶 、 碘化铵 、 calcium sulfate 、 正丁基锂 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 乙腈 为溶剂， 反应 5.5h， 生成
  参考文献：
  名称：

  Process development of potassium channel opener, TCV-295, based on convenient ring formation of 2H-1,3-benzoxazine and selective N-oxidation of the pyridyl moiety

  摘要：

  An efficient process for potassium channel opener, TCV-295, based on a novel and convenient 4-(2-pyridyl)-2H-1,3-benzoxazine ring formation from o-hydroxybenzoylpyridine by the NH4I/piperidine/2,2-dimethoxypropane system and the following selective pyridine-N-oxidation using dimethyldioxirane, has been developed. Additionally, the combination reagent of ammonium halide and sec- or tert- amine conveniently converted o-hydroxyphenyl arylketones with several ketones (or benzaldehyde) to various novel 4-aryl-2H-1,3-benzoxazines. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(01)00728-1
• 作为产物：
  描述：

  5-溴-4-氯水杨酸甲酯 在 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 以95%的产率得到5-溴-4-氯-2-羟基苯甲酸
  参考文献：
  名称：

  4,5-二卤代水杨酸的新型水杨酰苯胺：合成，抗菌活性和细胞毒性

  摘要：

  水杨酰苯胺已证明具有抗结核病（TB）的活性。水杨酸部分优选一个弱吸电子取代基，特别是4或5位的Cl或Br原子。另一方面，当强吸电子取代基（NO 2）出现在相同位置。本文中，我们描述了在水杨酸部分具有两个弱吸电子基团（卤素原子）的新型水杨酰苯胺的合成与表征，并将其抗结核活性与其单卤代类似物进行了比较。事实证明，所有二卤代衍生物在非常窄的微摩尔范围内（MIC = 1-4μM）都具有抗结核活性，与它们的活性最高的单卤代类似物相似。更重要的是，对最具活性的最终分子进行了进一步筛选，以抵抗多药耐药菌株，发现它们的生长抑制在0.5–4μM的范围内。

  DOI：

  10.1016/j.bmc.2017.01.016

文献信息

• Synthesis and Biological Activity of Novel 1,3-Benzoxazine Derivatives as K+ Channel Openers.
  作者：Satoshi YAMAMOTO、Shohei HASHIGUCHI、Shokyo MIKI、Yumiko IGATA、Toshifumi WATANABE、Mitsuru SHIRAISHI

  DOI：10.1248/cpb.44.734

  日期：——

  A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant

  设计了一系列在C4处带有2-吡啶1-氧化物基团的1,3-苯并恶嗪衍生物新系列，以探索新型的K +通道开放剂。通过使用亚氨基三氟甲磺酸的钯（0）催化的碳-碳键形成反应与有机锌试剂进行合成，并通过新的一锅一锅的苯甲酰基吡啶的1,3-苯并恶嗪骨架形成反应进行合成。测试了这些化合物在四乙基氯化铵（TEA）中的血管舒张活性，以及​​BaCl2诱导的和高KCl诱导的大鼠主动脉收缩，以确定潜在的K +通道开放剂，以及在自发性高血压大鼠中的口服降压作用。1,3-苯并恶嗪核的C6处具有适当形状的吸电子基团和C7处具有甲基或卤代基团是开发最佳血管舒张剂和降血压活性所必需的。特别是，
• [EN] INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF<br/>[FR] INHIBITEURS DE L'INTERACTION PROTÉINE-PROTÉINE DU DOMAINE BCL6 BTB ET LEURS UTILISATIONS
  申请人：ONTARIO INSTITUTE FOR CANCER RES OICR

  公开号：WO2019153080A1

  公开（公告）日：2019-08-15

  The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

  本申请涉及公式I（I）化合物或其药用可接受的盐、溶剂化合物和/或前药，包括含有这些化合物或药用可接受的盐、溶剂化合物和/或前药的组合物，以及在治疗可通过抑制与BCL6 BTB的相互作用可治疗的疾病、紊乱或状况中的各种用途，如癌症。
• Synthesis and Biological Activity of Novel 2-(.ALPHA.-Alkoxyimino)benzylpyridine Derivatives as K+ Channel Openers.
  作者：Tuyshi MAEKAWA、Satoshi YAMAMOTO、Yumiko IGATA、Shota IKEDA、Toshifumi WATANABE、Mitsuru SHIRAISHI

  DOI：10.1248/cpb.45.1994

  日期：——

  The search for novel K+ channel openers with a non-benzopyran skeleton, unlike cromakalim, led to the discovery of a new series of (Z)-2-(alpha-alkoxyimino)benzylpryridine derivatives. Synthesis was achieved by using a (Z)-dominant condensation reaction of benzoylpyridines with O-alkylhydroxylamines, followed by m-chloroperbenzoic acid (m-CPBA) oxidation. The compounds were tested for their vasorelaxant

  与cromakalim不同，寻找具有非苯并吡喃骨架的新型K +通道开放剂导致发现了一系列新的（Z）-2-（α-烷氧基亚氨基）苄基吡啶衍生物。合成是通过苯甲酰基吡啶与O-烷基羟胺的（Z）显性缩合反应，然后进行间氯过苯甲酸（m-CPBA）氧化而实现的。测试了这些化合物在四乙基氯化铵（TEA）和BaCl2中的血管舒张活性，以及​​高KCl诱导的大鼠主动脉收缩，以确定潜在的K +通道开放剂，以及它们在冠状动脉内注射后对冠脉血流（CBF）的影响。麻醉的狗。大量的2-（α-烷氧基亚氨基）苄基吡啶强烈抑制TEA和BaCl2诱导的收缩，对80 nM KCl诱导的收缩没有影响，并以10-30微克/只的狗将CBF增加至基础流量的200％以上。特别是（Z）-2- [5-溴-α-（叔丁氧基亚氨基）-4-氟-2-羟基苄基] -3-羟基吡啶1-氧化物（7d）表现出高度有效的血管舒张活性（EC50 = 0.28 microM
• 1,3-benzoxazine derivatives, their production and use
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US05270308A1

  公开（公告）日：1993-12-14

  A new compound of the formula: ##STR1## wherein ##STR2## is an optionally substituted benzene ring; R.sup.1 is a carbocyclic or heterocyclic group which is linked to the 4-position of the 1,3-benzoxazine ring through a carbon-carbon bond, a hydrocarbon residue, etc.; and R.sup.2 and R.sup.3 are independently a hydrogen atom or an optionally substituted C.sub.1-6 alkyl group, etc., or a salt thereof is useful for treating and preventing heart, circulatory, respiratory and cerebral diseases.

  一种新的化合物，化学式为: ##STR1## 其中 ##STR2## 是一个可选择取代的苯环; R.sup.1 是一个与1,3-苯并噁嗪环的4位通过碳-碳键、一个烃基残基等连接的碳环或杂环基团；R.sup.2 和 R.sup.3 分别是氢原子或一个可选择取代的C.sub.1-6烷基基团等，或其盐，用于治疗和预防心脏、循环、呼吸和脑部疾病。
• 水杨酸类化合物及其医药用途
  申请人：中国药科大学

  公开号：CN109748789A

  公开（公告）日：2019-05-14

  本发明公开了一种具有AMPK激动活性的水杨酸类化合物及其制备方法和医药用途，其为结构式如式(I)所示的化合物、其药学上可接受的盐或前药或溶剂化物。本发明的结构如式(I)所示的化合物激活AMPK，因而可用于制备预防或治疗AMPK介导的疾病的药物。